Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: Results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial

Circulation

Volumn 110, Issue 5, 2004, Pages 508-514

  Cohen, David J ^a,b   Bakhai, Ameet ^a,b,c   Shi, Chunxue ^a   Githiora, Louise ^a   Lavelle, Tara ^a   Berezin, Ronna H ^a   Leon, Martin B ^d   Moses, Jeffrey W ^d   Carrozza Jr , Joseph P ^b   Zidar, James P ^e   Kuntz, Richard E ^a  

^a HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d LENOX HILL HOSPITAL   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cost benefit analysis; Restenosis; Sirolimus; Stents

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; RAPAMYCIN;

ADULT; AGED; AORTA BALLOON; ARTICLE; BYPASS SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HOSPITAL COST; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; DOUBLE-BLIND METHOD; DRUG COSTS; EQUIPMENT DESIGN; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEALTH RESOURCES; HEART CATHETERIZATION; HOSPITAL COSTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; SIROLIMUS; STENTS; TICLOPIDINE; TREATMENT OUTCOME; UNITED STATES;

EID: 3543064732     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000136821.99814.43     Document Type: Article

References (18)

1. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 1998;352:673-681.
2. Rankin JM, Spinelli JJ, Carere RG, et al. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. N Engl J Med. 1999;341:1957-1965.
3. Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002;40:2082-2089.
4. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
5. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;34:1315-1323.
6. O'Neill WW, Leon MB. Drug-eluting stents: costs versus clinical benefit. Circulation. 2003;107:3008-3011.
7. Cohen DJ, Krumholz HM, Sukin CA, et al. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty: results from a randomized clinical trial. Circulation. 1995;92:2480-2487.
8. Taira DA, Seto TB, Siegrist R, et al. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. Am Heart J. 2003;145:452-458.
9. Cohen DJ, Taira DA, Berezin RH, et al. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the Stent-PAMI trial. Circulation. 2001;104:3039-3045.
10. Cohen DJ, Cosgrove RS, Berezin RH, et al. Cost-effectiveness of gamma radiation for treatment of in-stent restenosis: results from the Gamma-1 trial. Circulation. 2002;106:691-697.
11. Weintraub WS, Ghazzal ZM, Douglas JS Jr, et al. Long-term clinical follow-up in patients with angiographic restudy after successful angioplasty. Circulation. 1993;87:831-840.
12. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
13. Seto TB, Cohen DJ. Cost-effectiveness of adjunctive intracoronary brachytherapy for the treatment of in-stent restenosis. Vascular Radiotherapy Monitor. 2001:4:9-15.
14. Greenberg D, Bakhai A, Neumann PJ, et al. Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study. Health Policy. In press.
15. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine, part I. Circulation. 2002;106:516-520.
16. Kong DF, Eisenstein EL, Sketch MH, et al. Economic impact of drug-eluting stents on hospital systems: a disease-state model. Am Heart J. 2004;147:449-456.
17. Williams DO, Holubkov R, Yeh W, et al. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation. 2000;102:2945-2951.
18. Kiemeneij F, Serruys PW, Macaya C, et al. Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial. J Am Coll Cardiol. 2001;37:1598-1603.